When the results of the SELECT trial landed in the New England Journal of Medicine in November 2023, they confirmed what cardiologists had been hoping to see for years: a weekly injection of semaglutide, the drug behind Wegovy, cut the rate of heart attacks, strokes, and cardiovascular deaths by 20 percent in people with obesity and established heart disease who did not have diabetes. By March 2024, the U.S. Food and Drug Administration had expanded Wegovy’s label to include cardiovascular risk reduction, making it the first weight-loss medication ever approved specifically to prevent serious cardiac events. Now, as of mid-2026, additional pooled analyses and real-world data continue to reinforce those findings, and the conversation among clinicians has shifted from whether GLP-1 drugs protect the heart to how to get them to the patients who need them most.
What the SELECT trial showed
SELECT enrolled 17,604 adults aged 45 and older who had a body mass index of at least 27, a history of atherosclerotic cardiovascular disease, and no diabetes diagnosis. Half received subcutaneous semaglutide at 2.4 mg per week; the other half received a placebo. Researchers tracked participants for a mean of roughly 40 months. The primary outcome was a three-part composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, collectively known as major adverse cardiovascular events (MACE).
The results were unambiguous. MACE occurred in 6.5 percent of the semaglutide group compared with 8.0 percent of the placebo group, a hazard ratio of 0.80 with a 95 percent confidence interval of 0.72 to 0.90. The benefit appeared early, with the event curves separating within the first year, and it held across prespecified subgroups regardless of starting weight or baseline statin use. The trial’s protocol and endpoints were registered in advance on ClinicalTrials.gov under identifier NCT03574597, a safeguard against selective reporting that strengthens confidence in the published results.
Notably, the cardiovascular benefit was not simply a byproduct of dramatic weight loss. While participants on semaglutide lost an average of about 9.4 percent of their body weight, secondary analyses suggested that improvements in C-reactive protein, blood pressure, and waist circumference each contributed independently to the lower event rate. That pattern points to anti-inflammatory and metabolic effects that go beyond the scale.
Evidence beyond a single trial
SELECT is the landmark study, but it does not stand alone. Pooled analyses of randomized controlled trials examining GLP-1 receptor agonists in people with overweight or obesity and without diabetes have reported consistent reductions in MACE, myocardial infarction, and all-cause mortality across the drug class. A 2024 umbrella review published in a leading cardiovascular journal graded the certainty of evidence for multiple endpoints, finding high confidence for the MACE composite and moderate confidence for individual components like stroke and heart failure hospitalization.
Heart failure data have added another dimension. The STEP-HFpEF trial, also published in the New England Journal of Medicine, showed that semaglutide significantly improved symptoms, physical limitations, and exercise function in patients with heart failure with preserved ejection fraction and obesity. While that trial was not powered to detect differences in hard cardiovascular events like death, it demonstrated that the drug’s benefits extend into a heart failure population that has historically had few effective treatments.
Taken together, the evidence base now spans multiple trials, multiple endpoints, and multiple patient populations, all pointing in the same direction: GLP-1 receptor agonists offer cardiovascular protection that is clinically meaningful and statistically robust in people carrying excess weight.
What remains uncertain
Strong as the data are, several questions remain open. The most pressing is durability. SELECT’s follow-up of roughly 40 months is substantial for a cardiovascular outcomes trial, but it cannot tell us whether the benefit holds at five, seven, or ten years. If patients stop the drug, early evidence suggests that weight regain is common, and it is unclear whether the cardiovascular protection disappears along with the lost pounds or whether some residual benefit persists from the period of treatment.
Real-world adherence is another concern. Patients in randomized trials take their medications more consistently and receive closer monitoring than the general population. Semaglutide requires a weekly self-injection, and in SELECT, roughly 17 percent of participants in the active arm discontinued treatment, with gastrointestinal side effects (nausea, vomiting, diarrhea) being the most common reason. If discontinuation rates are higher outside the trial setting, the population-level impact could be smaller than the trial numbers suggest.
Subgroup data also need filling in. Published analyses from SELECT have shown consistent benefit across age groups and baseline BMI categories, but detailed breakdowns by race and ethnicity remain limited. Given that cardiovascular disease burden falls disproportionately on Black and Hispanic adults in the United States, understanding whether these groups experience the same relative and absolute benefit is essential for equitable prescribing.
Then there is the question of competition. Eli Lilly’s tirzepatide, marketed as Mounjaro and Zepbound, targets both GLP-1 and GIP receptors and produces even greater weight loss than semaglutide in head-to-head comparisons. Its dedicated cardiovascular outcomes trial, SURPASS-CVOT, is ongoing, and results are expected to clarify whether tirzepatide offers similar or superior cardiac protection. Until those data arrive, semaglutide remains the only GLP-1-class drug with a proven cardiovascular indication in people without diabetes.
The cost and access problem
Clinical efficacy means little if patients cannot get the drug. Wegovy carries a list price of roughly $1,300 per month in the United States, and while manufacturer savings programs and negotiated rates can lower out-of-pocket costs, coverage remains inconsistent. Many commercial insurers impose prior authorization requirements, step therapy protocols, or outright exclusions for weight-loss medications. Medicare, which covers a large share of the cardiovascular disease population, has historically excluded anti-obesity drugs from Part D formularies, though legislative efforts to change that policy have gained momentum.
The FDA’s cardiovascular indication has shifted the framing. Wegovy is no longer just a weight-loss drug in the eyes of regulators; it is a cardiac risk-reduction therapy. That distinction matters for coverage decisions, and some insurers have begun to loosen restrictions for patients who meet the SELECT trial’s eligibility criteria. But access remains uneven, and for many patients, the practical barrier is not clinical evidence but price.
What patients and doctors should weigh now
For adults with established cardiovascular disease, a BMI of 27 or higher, and no diabetes, the evidence as of mid-2026 supports a serious conversation about adding semaglutide to standard care. That standard care still includes statins, blood pressure medications, antiplatelet agents, and lifestyle modifications. GLP-1 therapy is additive, not a replacement. The 20 percent MACE reduction observed in SELECT was on top of guideline-directed therapy, meaning participants were already on the treatments their doctors would normally prescribe.
The decision is not automatic. Clinicians should weigh baseline cardiovascular risk, prior response to lifestyle interventions, tolerance for injectable therapy, and the likelihood of sustained adherence. Patients should know that gastrointestinal side effects are common in the first weeks, that the drug requires ongoing use to maintain benefits, and that stopping treatment may reverse both weight loss and cardiac protection.
What has changed is the category these drugs occupy. GLP-1 receptor agonists have crossed from the domain of cosmetic weight management into evidence-based cardiovascular medicine. The SELECT trial provided the proof. The FDA validated it. And the remaining questions, about long-term durability, equitable access, and whether newer drugs in the class will match or exceed semaglutide’s cardiac benefits, are the questions of a field that has already accepted the premise and is now working out the details.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
